Summit Therapeutics has expanded its clinical programme for ivonescimab with the Phase II/III HARMONi-GU1 study to assess its use in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

The post Summit Therapeutics begins Phase II/III HARMONi-GU1 study of ivonescimab appeared first on Clinical Trials Arena.